Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03720847 · ClinicalTrials.gov registry record · Phase 4
Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03720847 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants.
The verdict
NCT03720847, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) natural perimenstrual withdrawal from estradiol and progesterone (during placebo), (2) perimenstrual stabilization of estradiol and progesterone using transdermal estradiol and oral micronized progesterone.
Interventions
- DRUG Placebo capsule
- DRUG Oral Micronized Progesterone
- DRUG Estradiol Transdermal Patch 0.1 mg/24 hrs
- DRUG Inactive Clear Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-12-31 |
| Est. Completion | 2017-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03720847
The ClinicalTrials.gov registry entry for NCT03720847 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo capsule is the first listed.
NCT03720847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03720847 about?
NCT03720847 is a clinical study titled "Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality". This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) natural perimenstrual withdrawal f...
What is the current status of trial NCT03720847?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2016-12-31. Estimated completion is 2017-11.
What interventions are being tested in trial NCT03720847?
The interventions under investigation include: Placebo capsule (DRUG), Oral Micronized Progesterone (DRUG), Estradiol Transdermal Patch 0.1 mg/24 hrs (DRUG), Inactive Clear Patch (DRUG).
Who is sponsoring clinical trial NCT03720847?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.